Unique innovative anti-peptides mAbs

Osteoarthritis occurs when the cartilage that cushions the ends of bones in your joints gradually deteriorates. In osteoarthritis, the slick surface of the cartilage becomes rough. The disease is a degenerative one that worsens over time. Joint pain and stiffness may become severe enough to make daily tasks difficult.


Artialis has been able to identify innovative biomarkers involved into osteoarthritis and wishes to generate high-affinity mAbs against specific section: 9 amino acid sequence which comes from the type II collagen.



SynAbs has been able to generate high affinity and specific mAbs against all designed peptides.


An ELISA kit has consequently been successfully developed allowing the analysis of patients sera and urine to help confirming diagnosis.



" Our project on joint health degradation biomarker was not on the right track and so we were considering a smart way to bounce back and forth. SynAbs was the solution. They’re highly specialized in mAb field, have proved to be a proactive provider, with high commitment to build a long-term partnership "


Yves Henrotin,

Founder of Artialis